SCHEMBL24007919

SCHEMBL24007919

CC(C)n1nc(C2CC2)cc(NC(=O)C(C)(C)C)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TMIGD3 P0DMS9 1/20 0.43
▸ ADORA1 P30542 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ GAA P10253 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ BRPF1 P55201 1/20 0.34
▸ PDE10A Q9Y233 2/20 0.34
▸ MITF O75030 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ KLF5 Q13887 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ RET P07949 1/20 0.34
▸ MAT2A P31153 1/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.32
▸ PSMD14 O00487 1/20 0.32
▸ PTGER3 P43115 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24007637 0.83 ADORA1 (0.46) TMIGD3ADORA1SMN1; SMN2KDM4EGAA
SCHEMBL24007902 0.79 KDM4E (0.41) SMN1; SMN2KDM4EKMT2AGAABRPF1
SCHEMBL24567226 0.75 TMIGD3 (0.39) TMIGD3ADORA1GAACYP3A4CYP2C19
SCHEMBL24567211 0.75 TMIGD3 (0.39) TMIGD3ADORA1GAACYP3A4CYP2C19
SCHEMBL25745926 0.74 KDM4E (0.36) SMN1; SMN2KDM4EKMT2AGAACYP3A4
SCHEMBL14375500 0.73 KDM4E (0.40) KDM4EKMT2AGAACYP3A4CYP2C19
SCHEMBL24567218 0.73 TMIGD3 (0.37) TMIGD3ADORA1GAACYP3A4CYP2C19
SCHEMBL24567217 0.72 TMIGD3 (0.37) TMIGD3ADORA1GAACYP3A4CYP2C19
SCHEMBL25745860 0.72 KDM4E (0.38) SMN1; SMN2KDM4EKMT2ARETTLR9
SCHEMBL24007926 0.71 RET (0.40) SMN1; SMN2KDM4EKMT2ARET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 — — US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 — — US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 — — US disclosed
US-20220411403-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2022-12-29 — — US disclosed
WO-2021226261-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411403-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B TMIGD3 3941/4885ADORA1 4060/4885SMN1; SMN2 4718/4885
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B TMIGD3 3941/4885ADORA1 4060/4885SMN1; SMN2 4718/4885
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B TMIGD3 3941/4885ADORA1 4060/4885SMN1; SMN2 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback